Francisco J Carrillo-Salinas

Dr. Francisco J Carrillo-Salinas

Tufts University School of Medicine, Boston, Massachusetts, USA
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Neurobiology of Disease
Verified
Journal Article
Open access
MMM. Mecha
M. Mecha
AFA. Feliú
A. Feliú
PIP.M. Iñigo
P.M. Iñigo
LMLeyre Mestre
Leyre Mestre
FCFrancisco J Carrillo-Salinas
Francisco J Carrillo-Salinas
CGC. Guaza
C. Guaza
Inflammation in the central nervous system (CNS) is a complex process that involves a multitude of molecules and effectors, and it requires the transmigration of blood leukocytes across the blood-brain barrier (BBB) and the activation of resident immune cells. Cannabidiol (CBD), a non-psychotropic cannabinoid constituent of Cannabis sativa, has potent anti-inflammatory and immunosuppressive properties. Yet, how this compound modifies the deleterious effects of inflammation in TMEV-induced demyelinating disease (TMEV-IDD) remains unknown. Using this viral model of multiple sclerosis (MS), we demonstrate that CBD decreases the transmigration of blood leukocytes by downregulating the expression of vascular cell adhesion molecule-1 (VCAM-1), chemokines (CCL2 and CCL5) and the proinflammatory cytokine IL-1β, as well as by attenuating the activation of microglia. Moreover, CBD administration at the time of viral infection exerts long-lasting effects, ameliorating motor deficits in the chronic phase of the disease in conjunction with reduced microglial activation and pro-inflammatory cytokine production. Adenosine A2A receptors participate in some of the anti-inflammatory effects of CBD, as the A2A antagonist ZM241385 partially blocks the protective effects of CBD in the initial stages of inflammation. Together, our findings highlight the anti-inflammatory effects of CBD in this viral model of MS and demonstrate the significant therapeutic potential of this compound for the treatment of pathologies with an inflammatory component.

18 September 2018 in Circulation
Verified
Journal Article
Open access
PDF file
IVIñigo Valiente-Alandi
Iñigo Valiente-Alandi
SPSarah J. Potter
Sarah J. Potter
ASAne M. Salvador
Ane M. Salvador
ASAllison E. Schafer
Allison E. Schafer
TSTobias Schips
Tobias Schips
BBBurns C. Blaxall
Burns C. Blaxall
Background: Fibronectin (FN) polymerization is necessary for collagen matrix deposition and is a key contributor to increased abundance of cardiac myofibroblasts (MFs) after cardiac injury. We hypothesized that interfering with FN polymerization or its genetic ablation in fibroblasts would attenuate MF and fibrosis and improve cardiac function after ischemia/reperfusion (I/R) injury. Methods: Mouse and human MFs were used to assess the impact of the FN polymerization inhibitor (pUR4) in attenuating pathological cellular features such as proliferation, migration, extracellular matrix deposition, and associated mechanisms. To evaluate the therapeutic potential of inhibiting FN polymerization in vivo, wild-type mice received daily intraperitoneal injections of either pUR4 or control peptide (III-11C) immediately after cardiac surgery for 7 consecutive days. Mice were analyzed 7 days after I/R to assess MF markers and inflammatory cell infiltration or 4 weeks after I/R to evaluate long-term effects of FN inhibition on cardiac function and fibrosis. Furthermore, inducible, fibroblast-restricted, FN gene–ablated (Tcf21 MerCreMer ; Fn flox ) mice were used to evaluate cell specificity of FN expression and polymerization in the heart. Results: pUR4 administration on activated MFs reduced FN and collagen deposition into the extracellular matrix and attenuated cell proliferation, likely mediated through decreased c-myc signaling. pUR4 also ameliorated fibroblast migration accompanied by increased β1 integrin internalization and reduced levels of phosphorylated focal adhesion kinase protein. In vivo, daily administration of pUR4 for 7 days after I/R significantly reduced MF markers and neutrophil infiltration. This treatment regimen also significantly attenuated myocardial dysfunction, pathological cardiac remodeling, and fibrosis up to 4 weeks after I/R. Last, inducible ablation of FN in fibroblasts after I/R resulted in significant functional cardioprotection with reduced hypertrophy and fibrosis. The addition of pUR4 to the FN-ablated mice did not confer further cardioprotection, suggesting that the salutary effects of inhibiting FN polymerization may be mediated largely through effects on FN secreted from the cardiac fibroblast lineage. Conclusions: Inhibiting FN polymerization or cardiac fibroblast gene expression attenuates pathological properties of MFs in vitro and ameliorates adverse cardiac remodeling and fibrosis in an in vivo model of heart failure. Interfering with FN polymerization may be a new therapeutic strategy for treating cardiac fibrosis and heart failure.

2 October 2017 in Journal of Experimental Medicine
Verified
Journal Article
Open access
TNTania Nevers
Tania Nevers
ASAne M. Salvador
Ane M. Salvador
FVFrancisco Velazquez
Francisco Velazquez
NNNjabulo Ngwenyama
Njabulo Ngwenyama
FCFrancisco J Carrillo-Salinas
Francisco J Carrillo-Salinas
PAPilar Alcaide
Pilar Alcaide
Despite emerging data indicating a role for T cells in profibrotic cardiac repair and healing after ischemia, little is known about whether T cells directly impact cardiac fibroblasts (CFBs) to promote cardiac fibrosis (CF) in nonischemic heart failure (HF). Recently, we reported increased T cell infiltration in the fibrotic myocardium of nonischemic HF patients, as well as the protection from CF and HF in TCR-α−/− mice. Here, we report that T cells activated in such a context are mainly IFN-γ+, adhere to CFB, and induce their transition into myofibroblasts. Th1 effector cells selectively drive CF both in vitro and in vivo, whereas adoptive transfer of Th1 cells, opposite to activated IFN-γ−/− Th cells, partially reconstituted CF and HF in TCR-α−/− recipient mice. Mechanistically, Th1 cells use integrin α4 to adhere to and induce TGF-β in CFB in an IFN-γ–dependent manner. Our findings identify a previously unrecognized role for Th1 cells as integrators of perivascular CF and cardiac dysfunction in nonischemic HF.

1 October 2015 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
MMM. Mecha
M. Mecha
AFA. Feliú
A. Feliú
FCFrancisco J Carrillo-Salinas
Francisco J Carrillo-Salinas
ARA. Rueda-Zubiaurre
A. Rueda-Zubiaurre
Silvia Ortega-GutiérrezSilvia Ortega-Gutiérrez
Silvia Ortega-Gutiérrez
CGC. Guaza
C. Guaza

14 September 2012 in Journal of Neuroimmune Pharmacology
Verified
Journal Article
Closed access
PDF file
AGAitor G. Granja
Aitor G. Granja
FCFrancisco J Carrillo-Salinas
Francisco J Carrillo-Salinas
APAlberto Pagani
Alberto Pagani
MGMaría Gómez-Cañas
María Gómez-Cañas
RNRoberto Negri
Roberto Negri
EEduardo Muñoz
Eduardo Muñoz

19 September 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FLFernando Laso-García
Fernando Laso-García
JRJaime Ramos-Cejudo
Jaime Ramos-Cejudo
FCFrancisco J Carrillo-Salinas
Francisco J Carrillo-Salinas
Laura Otero-OrtegaLaura Otero-Ortega
Laura Otero-Ortega
AFAna Feliú
Ana Feliú
María Gutiérrez-FernándezMaría Gutiérrez-Fernández
María Gutiérrez-Fernández
Extracellular vesicles (EVs) have emerged as important mediators of intercellular communication and as possible therapeutic agents in inflammation-mediated demyelinating diseases, including multiple sclerosis (MS). In the present study, we investigated whether intravenously administered EVs derived from mesenchymal stem cells (MSCs) from human adipose tissue might mediate recovery in Theiler’s murine encephalomyelitis virus (TMEV)-induced demyelinating disease, a progressive model of MS. SJL/J mice were subjected to EV treatment once the disease was established. We found that intravenous EV administration improved motor deficits, reduced brain atrophy, increased cell proliferation in the subventricular zone and decreased inflammatory infiltrates in the spinal cord in mice infected with TMEV. EV treatment was also capable of modulating neuroinflammation, given glial fibrillary acidic protein and Iba-1 staining were reduced in the brain, whereas myelin protein expression was increased. Changes in the morphology of microglial cells in the spinal cord suggest that EVs also modulate the activation state of microglia. The clear reduction in plasma cytokine levels, mainly in the Th1 and Th17 phenotypes, in TMEV mice treated with EVs confirms the immunomodulatory ability of intravenous EVs. According to our results, EV administration attenuates motor deficits through immunomodulatory actions, diminishing brain atrophy and promoting remyelination. Further studies are necessary to establish EV delivery as a possible therapy for the neurodegenerative phase of MS.